Thursday, 21 April 2022
IDH RELEASES FY2021 FINANCIAL RESULTS
(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, released today its audited financial statements and operational performance for the year ended 31 December 2021, reporting revenue of EGP 5,225 million, up 97% compared to FY 2020. Profitability came in at an all-time high, with adjusted EBITDA growing 116% year-on-year to record EGP 2,530 million, and net profit recording a 145% year-on-year increase to reach EGP 1,493 million in FY 2021.
Tap or click here to read the full earnings release in pdf.
Attachments
Original Link
Original Document
Permalink
Disclaimer
IDH - Integrated Diagnostics Holdings plc published this content on 21 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 April 2022 11:04:06 UTC.
Integrated Diagnostics Holdings PLC is a consumer healthcare company. The Company operates in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Company is engaged in offering services in immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, histopathology, genetics, radiology and others. The Companyâs brands include Al Borg Scan, Al Mokhtabar, Ultralab, Biolab, Echo-Lab and others. It operates in approximately 552 branches. It offers more than 3,000 diagnostics tests ranging from routine to advanced. Its common tests include those for cholesterol, diabetes, pregnancy and substance abuse. Through Al Borg Scan, it offers a full range of radiology services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography-computed tomography (PET-CT), electromyography (EMG), electrocardiogram (ECG), electroencephalogram (EEG), ultrasound, x-ray, mammograms and cath lab facilities.